Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Angiotensin converting enzyme genotypes and mortality from COVID-19: An ecological study

Ar K Aung\textsuperscript{a,b,*}, Tess Aitken\textsuperscript{a}, Bing M Teh\textsuperscript{c}, Christiaan Yu\textsuperscript{d}, Richard Ofori-Asenso\textsuperscript{a,e}, Ken L Chin\textsuperscript{a,f}, Danny Liew\textsuperscript{a,b,**}

\textsuperscript{a} School of Public Health and Preventive Medicine, Monash University, Level 4, 553 St Kilda Road, Melbourne, VIC 3004, Australia
\textsuperscript{b} Department of General Medicine, Alfred Health, 55 Commercial Road, Melbourne, VIC 3004, Australia
\textsuperscript{c} Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia
\textsuperscript{d} Allergy, Immunology and Respiratory Medicine Department, Alfred Health, Melbourne, Australia
\textsuperscript{e} Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
\textsuperscript{f} Melbourne Medical School, University of Melbourne, Melbourne, Australia

\textbf{SUMMARY}

\textbf{Background:} Angiotensin converting enzyme (ACE) genotypes are known to be associated with development of acute respiratory distress syndrome (ARDS) and resultant mortality. In the present study, we examined the association between distribution frequency of ACE genotypes and COVID-19 mortality.

\textbf{Methods:} We undertook an ecological study to examine the association between ACE genotypes and COVID-19 mortality across 25 countries to represent different geographical regions of the world. The population frequencies of ACE genotypes were drawn from previously published reports and data on COVID-19-related mortality were extracted from ‘Worldometer’. Multivariable analyses were also undertaken adjusting for age (median age), sex (percentage of females) and the number of COVID-19 tests undertaken.

\textbf{Results:} The frequency of II genotype is highest in east Asian countries and lower among the European and African countries. An inverse geographical distribution frequency was noted for DD genotype. Increasing II genotype frequency was significantly associated with decreased COVID-19 mortality rates (adjusted incident rate ratio [IRR] 0.3, 95\% confidence interval [CI]: 0.002–0.7, \(p=0.03\)). However, no association was found between DD genotype frequency and COVID-19 mortality rates (adjusted IRR 4.3, 95\% CI: 0.5–41.2, \(p=0.2\)).

\textbf{Conclusions:} Distribution frequency of ACE insertion/insertion (II) genotype may have a significant influence on COVID-19 mortality. This information has potential utility for resource planning at a systemic level, as well as for clinical management.

\copyright 2020 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

\textbf{Introduction}

The coronavirus disease 2019 (COVID-19), caused by SARS-CoV2 virus, has evolved rapidly into a pandemic, with total confirmed cases of nearly 9 million, and more than 460,000 deaths worldwide as of 22 June 2020.\textsuperscript{1} The COVID-19 fatality rates vary greatly across countries, and have been attributed to multiple factors including availability of healthcare resources and mitigation strategies, including border closures, social distancing, mass screening, contact tracing and quarantine.\textsuperscript{2,3}

The clinical presentation of COVID-19 ranges from mild symptoms to potentially fatal respiratory failure due to development of adult respiratory distress syndrome (ARDS). The renin-angiotensinaldosterone system (RAAS) has been implicated in the pathogenesis of COVID-19.\textsuperscript{4} Moreover, the role of angiotensin converting enzymes 1 and 2 (ACE and ACE2) in the development of ARDS is well established.\textsuperscript{5} The coronavirus utilises membrane bound ACE2 receptors for entry into alveolar epithelial cells. This disrupts counter regulatory mechanisms between ACE and ACE2, leading to endothelial dysfunction and activation of severe maladaptive immune responses, the hallmark of ARDS.\textsuperscript{5,6}

https://doi.org/10.1016/j.jinf.2020.11.012
0163-4453\copyright 2020 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Please cite this article as: A.K. Aung, T. Aitken, B.M. Teh et al., Angiotensin converting enzyme genotypes and mortality from COVID-19: An ecological study, Journal of Infection, https://doi.org/10.1016/j.jinf.2020.11.012
The ACE gene is known to consist of two variant alleles; insertion (I) and deletion (D) polymorphisms.\(^7\) The allelic distribution of the ACE gene within a population follows the Hardy-Weinberg equilibrium, with three distinct genotypes: II, ID, and DD.\(^8\) Diseases such as stroke and diabetic nephropathy have been shown to be associated with the DD genotype.\(^9,10\) Additionally, previous studies on patients with sepsis (not due to coronavirus) demonstrated an association between DD genotype and development of ARDS resulting in higher mortality risk.\(^11\) On the other hand, the II genotype is associated with decreased mortality from ARDS.\(^12\) The ACE genotype distributions vary across geographical regions, with frequency of DD genotype being lowest among east Asian populations and highest among Caucasian and African populations.\(^8\)

Recent studies demonstrate that infection with COVID-19 may be associated with I/D polymorphisms, with increasing D allele frequency correlating to a reduction in prevalence but increase in mortality from COVID-19 infection.\(^13,14\) Currently, it remains unclear whether the observed variations in COVID-19 mortality among countries can be explained by variations in ACE polymorphisms, specifically in relation to the frequency of the II and DD genotypes. Hence, we undertook an ecological study to examine the association between the distribution frequency of ACE genotypes and COVID-19 mortality in selected countries representing different geographical regions of the world.

**Methods**

**Genotype frequency data**

Data on the distribution of ACE genotypes were collected for 25 countries representing a diverse cross-section of geographical regions of the world (Table 1). The data were drawn from systematic reviews and meta-analyses published in the past 15 years (since 2005) examining ACE genotypes and risk of cardiovascular, respiratory, diabetes, renal and stroke diseases.\(^8,9,15-22\) Published studies in English which contained the largest cohort of patients were selected to represent each country. For countries where ACE genotype data were not available from systematic reviews and meta-analyses, further searching was conducted through PubMed and Google Scholar, using search terms ‘ACE polymorphisms +(country name)’ or ‘ACE genotype +(country name)’. The full list of citations for included studies can be found in Supplementary Materials. Selected studies for each country included genotype distribution data for healthy controls or general population and diseased populations, except for France, where data were not available for the general population. The combined data for healthy and diseased populations were taken as the overall genotype frequency of that particular country.

**COVID-19 data**

COVID-19 data as of 8 June 2020 were extracted from ‘Worldometer’, a website owned by Dadax providing daily updated coronavirus data since 15 February 2020.\(^23\) For each of the selected countries, we extracted data pertaining to the number of confirmed COVID-19 cases, date of the first reported case, number of deaths and number of tests. COVID-19 related death was defined as per Worldometer’s definition of cumulative number of deaths among detected cases (https://www.worldometers.info/coronavirus/about/). For countries in which the first case was reported prior to 15 February 2020, data of the first reported COVID-19 case was obtained from the ‘Our World in Data’ website, which presents updated figures provided by the European Centre for Disease Prevention and Control (ECDC).\(^24\) The United Nations population database was used to collect information regarding population, median age and gender distribution.\(^25\)
The ACE genotype distribution and adjusted mortality rates for each country are shown in Table 1. Overall, the DD genotype frequency was highest in east Asian countries, followed by the DI genotype. The highest frequency of the DD genotype, at 5%, was observed in east Asian countries. The DD genotype frequency in other countries was lower. Table 1 displays the correlation between COVID-19-related deaths per million people per day since the first reported case and the adjusted mortality rates for each country. Figure 1 displays the correlation between COVID-19-related deaths per million people per day since the first reported case and the adjusted mortality rates for each country. Figure 1 displays the correlation between COVID-19-related deaths per million people per day since the first reported case and the adjusted mortality rates for each country. Figure 1 displays the correlation between COVID-19-related deaths per million people per day since the first reported case and the adjusted mortality rates for each country. Figure 1 displays the correlation between COVID-19-related deaths per million people per day since the first reported case and the adjusted mortality rates for each country. Figure 1 displays the correlation between COVID-19-related deaths per million people per day since the first reported case and the adjusted mortality rates for each country. Figure 1 displays the correlation between COVID-19-related deaths per million people per day since the first reported case and the adjusted mortality rates for each country. Figure 1 displays the correlation between COVID-19-related deaths per million people per day since the first reported case and the adjusted mortality rates for each country. Figure 1 displays the correlation between COVID-19-related deaths per million people per day since the first reported case and the adjusted mortality rates for each country. Figure 1 displays the correlation between COVID-19-related deaths per million people per day since the first reported case and the adjusted mortality rates for each country. Figure 1 displays the correlation between COVID-19-related deaths per million people per day since the first reported case and the adjusted mortality rates for each country. Figure 1 displays the correlation between COVID-19-related deaths per million people per day since the first reported case and the adjusted mortality rates for each country.
alter the concentration of circulating and tissue ACE. In particular, deletion (DD) genotype is associated with higher serum levels of ACE compared to II or ID genotypes, and reduced tissue ACE2 expression, which may explain the reduced prevalence of COVID-19 infections but increasing propensity for a more severe disease.7,13

Previous studies have also highlighted the role of ACE in ARDS by demonstrating a direct correlation between measurable serum ACE levels and the course of ARDS.23 Additionally, ACE gene polymorphisms can determine the risk of ARDS and death from sepsis, with II genotype significantly favouring survival from ARDS at 28 days.11,12 ACE gene polymorphisms also serve as a risk factor for cardiovascular conditions, including hypertension, ischaemic heart disease, diabetes, renal disease and stroke.8,16,20,22 Recent large cohort studies demonstrated that patients with these comorbidities are also at a higher risk of death from COVID-19.16,26,28 All these findings support the hypothesis that ACE genotype can influence COVID-19 mortality.

There is significant interest in the potential effects of ACE inhibitors on the course of COVID-19.29,30 To date, no difference in mortality has been observed between COVID-19 patients taking and not taking ACE inhibitors.29 Furthermore, it is unknown how ACE genotypes affect binding of ACE inhibitors, while the capacity for these medications to affect SARS-CoV2 cellular entry remains unknown. Evaluation of the influence of ACE genotype and the pharmacokinetic properties of ACE inhibitors may be beneficial in the search for potential SARS-CoV2 therapies.

The main limitation of our study stems from use of data from only 25 countries, and some of the samples were over-represented by people with pre-existing diseases. However, the 25 countries are representative of their geographical regions in terms of ACE genotype profiles, as well as COVID-19 burden. The over-representation of people with pre-existing diseases for our ACE genotype data is mitigated by the fact that most COVID-19-related deaths occur among people with comorbidities.28 Additionally, genotype data in some countries, such as USA, Australia, South Africa and Singapore, may be represented by multiethnic populations. This limitation was overcome by analysis of country-specific mortality data, which included all ethnicities. Lastly, although we adjusted for some of

Table 2
Incident rate ratios and adjusted incident rate ratios for mortality according to DD and II genotypes.

| ACE genotypes | Overall | Q1 | Q2 | Q3 | Q4 |
|---------------|---------|----|----|----|----|
| DD            | 10.3 (0.4–243.4), p = 0.15 | 1.0 (ref) | 1.4 (0.4–5.0), p = 0.6 | 5.1 (1.8–14.3), p = 0.002 | 1.6 (0.3–8.8), p = 0.57 |
| II            | 0.02 (0.0004–0.6), p = 0.03 | 1.0 (ref) | 0.8 (0.2–2.8), p = 0.76 | 0.7 (0.2–2.2), p = 0.5 | 0.1 (0.02–0.6), p = 0.014 |

Adjusted IRR (95% CI)

| ACE genotypes | Overall | Q1 | Q2 | Q3 | Q4 |
|---------------|---------|----|----|----|----|
| DD            | 4.3 (0.5–41.2), p = 0.2 | 1.0 (ref) | 0.7 (0.2–3.3), p = 0.7 | 2.0 (0.5–8.2), p = 0.3 | 1.2 (0.3–4.7), p = 0.8 |
| II            | 0.3 (0.002–0.7), p = 0.03 | 1.0 (ref) | 1.1 (0.4–3.1), p = 0.9 | 0.6 (0.2–1.7), p = 0.3 | 0.2 (0.02–1.6), p = 0.1 |

CI: confidence interval; IRR: incident rate ratio; Q1: first quartile; Q2: second quartile; Q3: third quartile; Q4: fourth quartile; ref: reference.

IRR was adjusted for median age, sex (% female) and number of tests per million for each country.

* Statistical significance.
the potential confounders in our analysis, many factors such as population density, accurate registries, case definitions and mitigation policies may further contribute to observed differences in COVID-19 mortality rates.

The findings from our study may partly explain the differential mortality observed across the world and are aligned with current understanding of SARS-CoV2 and ARDS pathophysiology. The role of ACE genotype as a prognostic factor in COVID-19 warrants further investigation. At a systemic level, knowledge of geographical variations in ACE genotype may allow for better prediction of the course of COVID-19, allowing safeguards to be implemented early, particularly in terms of healthcare resource allocation. At an individual patient level, risk stratification involving ACE genotype may inform more targeted clinical care, ultimately improving patient outcomes to reduce morbidity and mortality from the COVID-19 pandemic.

Declaration of Competing Interest
None to declare.

Acknowledgement
None.

Funding
None.

Contributors’ statement
AKA - conception, literature search, study design, data collection, data analysis, data interpretation, writing and final approval.
TA - conception, literature search, data collection, data analysis, data interpretation, writing and final approval.
BMT - literature search, data collection, data interpretation, writing and final approval.
CY - conception, data interpretation, writing and final approval.
RO - data analysis, data collection, data interpretation, writing and final approval.
KLC - conception, study design, data analysis, data interpretation, writing and final approval.
DL - conception, study design, data analysis, data interpretation, writing and final approval.

Supplementary materials
Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.jinf.2020.11.012.

References
1. Organization WH. Coronavirus disease 2019 (COVID-19). Coronavirus disease 2019 (COVID-19), 154; 2020.
2. Joint Task Force on Practice Parameters Executive summary of disease management of drug hypersensitivity: a practice parameter. Ann Allergy Asthma Immunol 1999;83:665–700.
3. Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet 2020;395(10231):1225–8.
4. Vaduganathan M, Vardeny O, Michel T, McMurray JJ, Pfeffer MA, Solomon SD. Renin–angiotensin–aldosterone system inhibitors in patients with COVID-19. N Engl J Med 2020;382(17):1653–9.
5. Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury. Nat Med 2005;11(8):787–9.
6. Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ 2020;27(5):1451–6.
7. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86(4):1343–6.
8. Saab Y, Bard P, Overall A. The geographic distribution of the ACE II genotype: a novel finding. Genet Res Comb 2007;8(4):259–60.
9. Zhang Z, Xu G, Liu D, Fan X, Zhu W, Liu X. Angiotensin-converting enzyme insertion/deletion polymorphism contributes to ischemic stroke risk: a meta-analysis of 50 case-control studies. PLoS ONE 2012;7(10):e46495.
10. Marre M, Jeunemaître X, Gallos Y, Rodier M, Chatellier G, Sert C, et al. Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes: gene-tissue de la nephropathie diabétique (GENEDIAB) study group. J Clin Invest 1997;99(7):1955–95.
11. Marshall RP, Webb S, Bellingan GJ, Montgomery HE, Chaudhari B, McNulty RJ, et al. Angiotensin converting enzyme insertion/deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome. Am J Respir Crit Care Med 2002;166(5):646–50.
12. Jerig J-S, Yu C-J, Wang H-C, Chen K-Y, Cheng S-L, Yang P-C. Polymorphism of the angiotensin-converting enzyme gene affects the outcome of acute respiratory distress syndrome. Crit Care Med 2006;34(4):1901–6.
13. Delanghe JR, Speeckaert MM, De Buyzere ML. COVID-19 infections are also affected by human ACEI D/I polymorphism. Clin Chem Lab Med 2020;58(7):1125–6.
14. Delanghe JR, Speeckaert MM, De Buyzere ML. The host’s angiotensin-converting enzyme polymorphism may explain epidemiological findings in COVID-19 infections. Clin Chim Acta 2020;505:192–3.
15. Yako YY, Guewo-Fokeng M, Bali V, Bouatta-Naji N, Matsha TE, Sobjjwi E, et al. Genetic risk of type 2 diabetes in populations of the African continent: a systematic review and meta-analyses. Diabetes Res Clin Pract 2016;114:136–50.
16. Mengesha HG, Petrucka P, Spence C, Tafesse TB. Effects of angiotensin converting enzyme gene polymorphism on hypertension in Africa: a meta-analysis and systematic review. PLoS ONE 2019;14(4):e0211054.
17. Khodaeian M, Enayati S, Tabatabaee-Malazy O, Amoli MM. Association between genetic variants and diabetes mellitus in Iranian populations: a systematic review of observational studies. J Diabetes Res 2015;2015:585917.
18. Kang SW, Kim SK, Chung J-H, Jung H-J, Kim K-I, Kim J, et al. Genetic polymorphism of angiotensin-converting enzyme and chronic obstructive pulmonary disease risk: an updated meta-analysis. Biomed Res Int 2016;2016:7636123.
19. Ma Y, Tong X, Liu Y, Liu S, Xiong H, Fan H. ACE gene polymorphism is associated with COPD and COPD with pulmonary hypertension: a meta-analysis. Int J Chron Obstruct Pulmon Dis 2018;13:2435–46.
20. Smyth LJ, Cañadas-Garre M, Cappa RC, Maxwell AP, McKnight AJ. Genetic associations between genes in the renin-angiotensin-aldosterone system and renal disease: a systematic review and meta-analysis. BMJ Open 2019;9(4):e026777.
21. Niu W, Qi Y, Gao P, Zhu D. Association between angiotensin converting enzyme G2350A polymorphism and hypertension risk: a meta-analysis. J Renin Angiotensin Aldosterone Syst 2011;12(1):1–14.
22. ZJ, CHEN LS, ZHANG LC, ZHOU TB. Meta-analysis of the relationship between ACE I/D gene polymorphism and end-stage renal disease in patients with diabetic nephropathy. Nephrology 2012;17(5):480–7.
23. Worldometers.info. Worldometer COVID-19 coronavirus pandemic [Internet]. Dover, Delaware, U.S.A; 2020 Available from: https://www.worldometers.info/coronavirus/.
24. Roser M., Ritchie H., Ortiz-Ospina E., Hasell J. Coronavirus disease (COVID-19) [Internet]. Wales, UK: our world in data; 2020 Available from: https://ourworldindata.org/coronavirus.
25. World population prospects 2019 United Nations, Department of Economic and Social Affairs, population division2019. Available from: https://population.un.org/wpp/Download/Standard/Population/.
26. Richardson SH, Narasimhan M, Crawford JM, McGinn T, Barnaby DP, et al., Davidson K, Wand the Northwell COVID-19 Research Consortium Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 2020. doi: 10.1001/jama.2020.6775.
27. Fourrier F, Chopi C, Wallaert B, Mazuirer C, Mangalaboyi J, Durocher A. Compared evolution of plasma fibronectin and angiotensin-converting enzyme levels in septic ARDS. Chest 1985;87(2):191–5.
28. Zhou F, Yu T, Du R, Fan G, Li Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395(10229):1054–62.
29. Li J, Wang X, Chen J, Zhang H, Deng A. Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China. JAMA Cardiol. 2020;5(7):825–30.
30. Mancia G, Rea F, Iuliano M, Apolone G, Corrao G. Renin-angiotensin–aldosterone system blockers and the risk of Covid-19. N Engl J Med 2020;382:2341–40.